Sri Lanka pharmaceutical serialization is a regulatory initiative led by the National Medicines Regulatory Authority (NMRA) to combat counterfeit medicines and improve drug traceability. It requires pharmaceutical products to carry unique identification codes, enabling tracking from manufacturing through distribution to the patient, thereby enhancing patient safety and supply chain transparency.

In 2024, NMRA mandated that pharmaceutical packs include a QR code or barcode containing key product data such as product name, strength, batch number, manufacturing and expiry dates, price, and manufacturer details. Additionally, “NMRA approved” and retail price stickers became mandatory by October 2024 as part of early Sri Lanka pharmaceutical serialization efforts.

Serialization for imported pharmaceutical products was officially extended to December 31, 2025. From this date, imported packs must carry QR or 2D DataMatrix codes encoding product code, lot number, manufacturing date, expiry date, and a unique serial number in compliance with Sri Lanka pharmaceutical serialization regulations.

From December 2025, all imported pharmaceuticals must display the Maximum Retail Price (MRP) and the name and address of the local Marketing Authorization Holder (MAH) or importer. These details must be securely affixed or printed on the primary or secondary packaging to ensure full traceability under Sri Lanka pharmaceutical serialization rules.

Non-compliance may result in customs clearance delays, shipment rejections, regulatory penalties, and potential loss of market access. Companies exporting to Sri Lanka are strongly advised to align early with Sri Lanka pharmaceutical serialization timelines and adopt compliant labelling, serialization, and traceability technologies.